Carmen Peral

  • Citations Per Year
Learn More
• A decision tree model was performed (Figure 1). • The success (clinical and microbiological response) and safety (hepatic and renal adverse effects) of first-line treatments were obtained from meta-analyses and systematic reviews of clinical trials (Table 1). • In the case of failure, a second-line treatment (liposomal amphotericin B after the(More)
OBJECTIVES To evaluate the cost-effectiveness of first-line treatment of Overactive Bladder (OAB) with fesoterodine relative to mirabegron, from the Spanish National Health System (NHS) perspective. METHODS A decision tree model was developed to represent a typical clinical process of 52-week of treatment for an OAB patient with urge urinary incontinence(More)
ISPOR 18th Annual European Congress, 7-11 Nov 2014 , Milan, Italy The original study was funded by Pfizer, SLU. Carmen Peral and Javier Rejas are employed by Pfizer, SLU. Jaime Ramos is former employee of Pfizer Other authors claim to have no conflict of interest related to this study. o The CCA was populated with data from an observational, retrospective(More)
OBJECTIVE To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in Spain. MATERIALS AND METHODS A decision-tree model was applied. The success and safety (hepatic and(More)
Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven(More)
OBJECTIVE According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, mortality was lower after 6 weeks with VOR+ANI than with VOR monotherapy in a post(More)
OBJECTIVE To carry out cost-effectiveness analysis from the Spanish National Health System perspective, of treating overactive bladder (OAB), in newly diagnosed patients with two flexible doses of fesoterodine in routine clinical practice. PATIENTS AND METHODS Economic evaluation of flexible-dose fesoterodine in newly diagnosed patients, including two(More)
  • 1